CD8A and glioblastoma: For example, the TME of glioblastoma is largely myeloid in nature and lacks infiltrating CD8+ T cells; thus, targeting myeloid metabolism to shift the TME to a more inflamed phenotype could unlock the therapeutic benefits of anti-PD1 or other checkpoint blockades.